StocksMedium•12 October 2026•
1 min read
Bristol Myers Shares Fall 3% Despite Positive Cancer Drug Trial Results
Key Facts
1Bristol-Myers Squibb shares fell 3% to $57.39 despite announcing positive results from a late-stage clinical trial.
2The Phase 3 ACTION-1 trial of RYZ101 met its primary endpoint, showing significant improvement in progression-free survival for GEP-NET patients.
Bristol-Myers Squibb shares fell 3% to $57.39 despite the company announcing positive results from a late-stage clinical trial. Proactive Investors reported that the Phase 3 ACTION-1 trial of RYZ101 met its primary endpoint, demonstrating a significant improvement in progression-free survival for patients with advanced gastroenteropancreatic neuroendocrine tumours.
BMY closed at $59.12 on October 9, 2026, prior to the current decline. The company, through its subsidiary RayzeBio, developed RYZ101 to address treatment gaps for patients who progressed after initial therapies, and Bristol Myers now plans to discuss these findings with the US Food and Drug Administration regarding a future regulatory submission.